Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zoetis (NY: ZTS )

175.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Zoetis to Host Webcast and Conference Call on First Quarter 2022 Financial Results
From Zoetis Inc.
Via Business Wire
The New 'Return On Character' ETF Doesn't Include Musk Or Zuckerberg: Who Made The Cut?
A new active ETF launched this week with a unique spin on how it picks the companies to include in the fund. What Happened: ROC I... 
Via Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. 
Via InvestorPlace
Zoetis to Participate in the Bank of America Securities 2022 Animal Health Summit
From Zoetis Inc.
Via Business Wire
Zoetis: Q4 Earnings Insights
  Zoetis (NYSE:ZTS) reported its Q4 earnings results on Tuesday, February 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why This Petcare Stock Is Hitting Record Highs
The pet care sector was already growing rapidly, but the coronavirus pandemic has only accelerated its growth. 
Via Talk Markets
Zoetis's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Zoetis (NYSE:ZTS) posted Q4 earnings of $413.00 million, an increase from Q3 of 25.18%. Sales dropped to $1.97 billion, a 1.16% decrease between quarters. 
Via Benzinga
4 Top Stock Trades for Wednesday: NVDA, SPCE, ABNB, ZTS
Nvidia, Virgin Galactic, Airbnb and Zoetis were our top stock trades for Wednesday. Here's how the charts are setting up right now. 
Via InvestorPlace
Zoetis Tops Quarterly Forecasts As Spot And Fluffy Contribute To Sales Growth
Companion animal sales continued their lead with livestock sales falling again. 
Via Investor's Business Daily
Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook
Zoetis Inc (NYSE: ZTS) has reported Q4 FY21 revenue of $2 b 
Via Benzinga
Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook
Zoetis Inc. has reported Q4 FY21 revenue of $2 billion, an increase of 9% Y/Y, beating the consensus of $1.93 billion. 
Via Talk Markets
Zoetis Reports Fourth Quarter and Full Year 2021 Results
From Zoetis Inc.
Via Business Wire
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
Earnings Outlook For Zoetis
Zoetis (NYSE:ZTS) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that Zoetis will report an... 
Via Benzinga
Zoetis Declares Second Quarter 2022 Dividend
From Zoetis Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
7 of the Top-Rated Pharmaceutical Stocks for Q1
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
Zoetis's Ex-Dividend Date Is Tuesday, Here's What You Need To Know
Tuesday marks the last chance for investors to receive the next dividend payout from Zoetis. What's Happening (NYSE: 
Via Benzinga
FDA Approves Zoetis' Solensia To Control Osteoarthritis Pain In Cats
The FDA has approved Zoetis Inc's (NYSE: ZTS) Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their... 
Via Benzinga
Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats
From Zoetis Inc.
Via Business Wire
Zoetis Announces Expanded Commitments to Protect the Planet
From Zoetis Inc.
Via Business Wire
4 Top Stock Trades for Wednesday: AVGO, AMD, ARKK, ZTS
Advanced Micro Devices, Broadcom, the ARKK ETF and Zoetis were our top stock trades for Wednesday. Now, let's take a look at the charts. 
Via InvestorPlace
Zoetis to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Zoetis Inc.
Via Business Wire
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2021 Financial Results
From Zoetis Inc.
Via Business Wire
Price To Earnings Ratio Insights For Zoetis
In the current session, Zoetis Inc. (NYSE:ZTS) is trading at $229.83, after a 1.83% increase. Over the past month, the stock increased by 6.13%, and in the past year... 
Via Benzinga
Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B
The board of directors of Zoetis Inc (NYSE: ZTS) has approved a $3.5 billion share repurchase program. The company added that the new share buyback, spanning... 
Via Benzinga
Zoetis Announces Authorization of $3.5 Billion Share Repurchase Program
From Zoetis Inc.
Via Business Wire
Zoetis Named One of Newsweek’s Most Responsible Companies for 2022
From Zoetis Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years
Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 19.02% on an annualized basis. Buying $100.00 In ZTS: 5 years ago, an investor could have purchased 2.01... 
Via Benzinga
The ProShares Pet Care ETF Capitalizes on Our Love for Our Pets
Our little furry friends are part of an industry projected to be worth $350 billion by 2027. That's where the PAWZ ETF comes in. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.